(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Previous data from our institution suggest that imaging evidence of extracapsular extension, identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC head and neck squamous cell cancers.

Jerry T. Liu, MD, Benjamin H. Kann, BS, Michael Buckstein, MD, PhD, Richard Bakst, MD, Eric Genden, MD, Marshall Posner, MD, Peter Som, MD, Vishal Gupta, MD; Icahn School of Medicine at Mount Sinai

Background: Pathologic extracapsular extension (pECE) in locally advanced head and neck squamous cell cancers (HNCs) is associated with poor prognosis. Previous data from our institution suggest that imaging evidence of extracapsular extension (rECE), identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC HNCs.

Methods: From our departmental database, 121 patients with locally advanced (cN+) non-OPC HNCs were treated in our department with definitive or adjuvant radiation therapy (± induction chemotherapy and/or concurrent chemotherapy) from 2006–2012. Thirteen patients had recurrent disease at presentation, seven patients discontinued treatment due to noncompliance or other factors, two patients underwent reirradiation of the treated region, and three patients did not have accessible pretreatment CT studies. The remaining 96 patients (nasopharynx [n = 18], hypopharynx [n = 16], larynx [n = 22], oral cavity/lip [n = 24], nasal cavity/sinus [n = 3], and unknown primary [n = 13]) were selected for this study, and all pretreatment CT studies were reviewed by our head/neck radiologist for evidence of rECE. Patients were stratified by presence of rECE, age, gender, race (black vs nonblack), smoking history (≥ 10 vs < 10 pack-years), Eastern Cooperative Oncology Group (ECOG) performance status (PS), T-stage, N-stage, overall stage, and treatment type. Univariate and multivariate analyses were performed regarding the impact of these factors on locoregional control (LRC), distant control (DC), progression-free survival (PFS), and overall survival (OS). Patients who underwent initial neck dissection (n = 42) were analyzed for the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of rECE as a predictor for pECE.

Results: At a median follow-up of 27 months (range: 3–94 mo), 56 (58%) patients had rECE and 40 (42%) did not. These groups were well balanced for median age, gender, race, smoking history, PS, and treatment type. Patients with rECE were more likely to have cN2–3 disease versus those without rECE (86% vs 75%, respectively; P = .028). Patients with rECE had significantly worse LRC (3-yr: 67% vs 88%; P = .032), DC (3-yr: 69% vs 88%; P = .017), PFS (3-yr: 57% vs 79%; P = .017), and OS (3-yr: 57% vs 87%; P = .018). On multivariate analysis, rECE was found to be an independent predictor for worse LRC (hazard ratio [HR] = 3.83; 95% confidence interval [CI], 1.36–10.79), DC (HR = 3.71; 95% CI, 1.24–11.12), PFS (HR = 2.70; 95% CI, 1.19–6.11), and OS (HR = 2.87; 95% CI, 1.06–7.81). For patients who underwent definitive surgery, the sensitivity, specificity, PPV, and NPV of rECE to predict for pECE were 70%, 67%, 79%, and 56% respectively.

Conclusions: As previously reported for OPC, presence of rECE, compared with lack of rECE, portends worse prognosis for patients with non-OPC HNCs undergoing definitive or adjuvant radiation therapy. For these patients, presence of rECE is an independent predictor for worse LRC, DC, PFS, and OS. Further studies, with larger cohorts and longer follow-up, are needed to validate these findings and determine how rECE can be used to guide clinical management in these patients.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Related Content